Currently, there are 429.82M common shares owned by the public and among those 429.40M shares have been available to trade.
The company’s stock has a 5-day price change of 1.96% and -23.22% over the past three months. JHX shares are trading -22.40% year to date (YTD), with the 12-month market performance down to -22.19% lower. It has a 12-month low price of $19.72 and touched a high of $43.57 over the same period. JHX has an average intraday trading volume of 2.74 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.11%, 1.30%, and -24.22% respectively.
Institutional ownership of James Hardie Industries plc ADR (NYSE: JHX) shares accounts for 8.49% of the company’s 429.82M shares outstanding.
It has a market capitalization of $10.28B and a beta (3y monthly) value of 1.73. The stock’s trailing 12-month PE ratio is 24.47, while the earnings-per-share (ttm) stands at $0.98. The company has a PEG of 2.30 and a Quick Ratio of 1.67 with the debt-to-equity ratio at 0.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.01% over the week and 2.47% over the month.
Analysts forecast that James Hardie Industries plc ADR (JHX) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 1.82 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to increase by 0.36%, and 15.16% over the next financial year. EPS should shrink at an annualized rate of 10.63% over the next five years, compared to 12.44% over the past 5-year period.
Looking at the support for the JHX, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on March 27, 2025, with the firm’s price target at $27.40-$27.35. Macquarie was of a view on March 24, 2025 that the stock is Neutral, while Truist gave the stock Buy rating on December 10, 2024, issuing a price target of $45. JP Morgan on their part issued Overweight rating on November 06, 2024.
